Last week, On The Pen reported that Eli Lilly was working with the FDA to provide retatrutide through the agency’s expanded access, or compassionate use, pathway. This week, it happened.
According to STAT, a 79-year-old man has become the first known patient to receive retatrutide outside of a clinical trial.
The news is significant not because it changes access for the broader public, it doesn’t really. Expanded access remains rare and reserved for extraordinary circumstances. What it does signal is that retatrutide has officially moved beyond the confines of clinical research.
For patients living with obesity who have not responded adequately to current therapies, retatrutide represents one of the most anticipated medicines in development. Lilly’s triple-hormone agonist has produced weight loss results approaching 30% in late-stage studies, fueling expectations that it could become the next major advance in obesity medicine.
One patient receiving the drug won’t change the obesity epidemic. But it does represent a massive milestone for this community. For the first time, someone outside a clinical trial is receiving the next generation of obesity treatment. A week ago, this was a possibility. Today, it’s reality.
